SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

SAN DIEGO, Sept. 24, 2026 // -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent public offerings of 7,857,143 shares of c…

Related stories